N/A
N=98
Evaluation of Perioperative Celecoxib for Hip Arthroscopy
Hip Labral Tears
Bottom Line
View on ClinicalTrials.gov: NCT02779166 ↗Enrolled (actual)
98
Serious AEs
0.0%
Results posted
May 2019
Primary outcome: Primary: Visual Analog Score for Pain (VAS) in the Immediate Post Operative Period — 2.11; 2.33; 4.41; 5.02 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Celecoxib (Drug); placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Northwestern University
- Primary completion
- Jan 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Visual Analog Score for Pain (VAS) in the Immediate Post Operative Period |
2.11; 2.33; 4.41; 5.02; 4.63; 5.36 | — |
| PRIMARY Total Narcotic Consumption in the Post Anesthesia Care Unit (PACU) |
15.326; 15.419 | — |
| PRIMARY Time to Discharge Following Surgery |
152.9; 172.9 | — |
Summary
Celecoxib is commonly used for perioperative pain control for certain orthopaedic procedures. It has been shown to be successful in assisting in pain control for knee arthroscopy. It has not previously been studied in hip arthroscopy. This is a double blinded randomized controlled trial to determine the efficacy of celecoxib in perioperative pain control for hip arthroscopy.
Eligibility Criteria
Inclusion Criteria
- All patients who are undergoing a hip arthroscopy procedure at Northwestern Memorial Hospital with Dr. Michael Terry.
Exclusion Criteria
- Pregnant women and any patient under the age of 18 years.
Data sourced from ClinicalTrials.gov (NCT02779166). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.